William Oh, MD

Dr. Oh earned an MD from the New York University School of Medicine. He completed a general medicine residency at Brigham and Women's Hospital at Harvard Medical School in Boston. He completed a fellowship in medical oncology at the Dana Farber Cancer Institute.

Clinical interests include management of genitourinary malignancies, including prostate, renal, bladder, adrenocortical, and testicular cancers.

Research interests include exploring the role of chemotherapy in both castration-resistant prostate cancer (CRPC) and localized high-risk prostate cancer. In collaboration with laboratory-based colleagues, changes in the expression of tissue and serum biomarkers due to chemotherapy are being assessed. Another area of interest relates to the role of secondary hormone therapies in the treatment of advanced prostate cancer.

Another major research area has been the development and management of a prospective clinical database linked to blood and tissue banks for prostate cancer patients. Dr. Oh's recent research efforts exploring this database have included characterization of the efficacy of various therapies in advanced prostate cancer (e.g., nilutamide, ketoconazole, vinorelbine, docetaxel, mitoxantrone), assessment of PSA doubling time as a prognostic and predictive factor, efficacy of hormonal therapy, assessment of testosterone as a marker for cancer outcome, prediction of relapse based on nutritional factors at diagnosis and autoantibody signatures, and assessment of pharmacogenomic patterns predicting Gleason score.